Problems do not seem to thin for Ranbaxy Laboratories. The US Food and Drug Administration (FDA) has extended the ongoing consent decree with the company for its Paonta Sahib (Himachal) and Dewas (Madhya Pradesh) units to its third and newly commissioned manufacturing facility at Mohali (close to Chandigarh), which had attracted an import alert from the regulator on Friday. "The Mohali facility be subject to certain terms of the consent decree of permanent injunction entered against Ranbaxy in January 2012," said the American regulator on Monday. The consent decree means Ranbaxy would be barred from supplying any products from Mohali to the US until it takes all corrective action to the latter's satisfaction. FDA will re-inspect the facility before giving a go-ahead.